Bayer

News

Amgen shares down as heart failure drug disappoints in phase...

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.

R&D

A history of the pharmaceutical industry

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution

News

Bayer invests in digital health firm One Drop

Bayer strikes $98m deal with digital health firm One Drop

Bayer has taken a further stake in New York-based One Drop to support its plans to become a digital health business by developing new integrated care services for patients.

News

Bayer adds menopause drug to pipeline with KaNDy acquisition

Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline.

News

Bayer slides on €9.5bn loss caused by litigation, COVID-19 i...

Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer he

News

Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...

Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation, meaning Bayer’s class rival faces competition in Europe for

Amgen shares down as heart failure drug disappoints in phase...

A history of the pharmaceutical industry

Bayer strikes $98m deal with digital health firm One Drop

Bayer adds menopause drug to pipeline with KaNDy acquisition

Bayer slides on €9.5bn loss caused by litigation, COVID-19 i...

Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

Bayer

Editor's Picks